What are ADC's

Our services

ADC Review
is made possible by:

NCT01851200 (Clinical Trial/ Brentuximab vedotin)

Study Title
Brentuximab Vedotin (SGN-35) as Salvage Treatment for CD30-positive Germ Cell Tumors (NCT01851200)

Trial Description
The purpose of the study is to assess the activity of brentuximab vedotin (also known as SGN-035) in refractory germ cell tumors.

This trial is sponsored by Fondazione Michelangelo. [1]

Study data

  • Condition: Germ Cell Tumors
  • Interventions:
  • Phase: II
  • Estimated Enrollment: 9
  • Start: May 2013
  • Estimated Completion: June 2015
  • Last verified: January 2015

Study Schematic

NCT01851200 (Clinical Trial/ Brentuximab vedotin)


Last Editorial review: July 11, 2016
Information based on (NIH/NCI) and other sources.

Copyright © 2015 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.



Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...

Skip to toolbar